Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:41:469-508.
doi: 10.21775/cimb.041.469. Epub 2020 Sep 23.

Alphaherpesvirus Vaccines

Clare Burn Aschner  1 , Betsy C Herold  1
Affiliations
Review

Alphaherpesvirus Vaccines

Clare Burn Aschner et al. Curr Issues Mol Biol. 2021.

Abstract

Prophylactic and therapeutic vaccines for the alphaherpesviruses including varicella zoster virus (VZV) and herpes simplex virus types 1 and 2 have been the focus of enormous preclinical and clinical research. A live viral vaccine for prevention of chickenpox and a subunit therapeutic vaccine to prevent zoster are highly successful. In contrast, progress towards the development of effective prophylactic or therapeutic vaccines against HSV-1 and HSV-2 has met with limited success. This review provides an overview of the successes and failures, the different types of immune responses elicited by various vaccine modalities, and the need to reconsider the preclinical models and immune correlates of protection against HSV.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abendroth A et al., 2000. Modulation of major histocompatibility class II protein expression by varicella-zoster virus. Journal of Virology, 74(4), pp. 1900–1907. - PMC - PubMed
    1. Abendroth A et al., 2001. Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. Journal of Virology, 75(10), pp.4878–4888. - PMC - PubMed
    1. Admedus, 2018. ADMEDUS HSV 2 PHASE IIA RESULTS - MAY 2017.
    1. Ahn K et al., 1996. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. The EMBO journal, 15(13), pp. 3247–3255. - PMC - PubMed
    1. Argaw T et al., 2000. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. Journal of Infectious Diseases, 181(3), pp.1153–1157. - PubMed

MeSH terms